Answers are grounded in this paper and cite their sources.
Monoclonal antibodies represent one of biomedicine's greatest successes, yet global access remains profoundly inequitable, with low- and middle-income countries bearing the brunt of limited access. This perspective proposes that long-acting infectious disease mAbs, starting with WHO-recommended nirsevimab for RSV prevention, could catalyze transformation by connecting with existing WHO Essential Medicines List mAbs. Picture two static half-circles: WHO Essential Medicines List mAbs with proven value but limited access, and infectious disease prevention mAbs with transformative potential. Connected, they form a complete wheel capable of rolling toward the aspirations of global pharmacoequity. HIV antiretroviral therapy demonstrates precedent-costs declined 100-fold through political mobilization, not technological breakthroughs.
No takes yet. Share an insight, caveat, or question.
Gelderblom et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: